JP2016535769A5 - - Google Patents

Download PDF

Info

Publication number
JP2016535769A5
JP2016535769A5 JP2016551037A JP2016551037A JP2016535769A5 JP 2016535769 A5 JP2016535769 A5 JP 2016535769A5 JP 2016551037 A JP2016551037 A JP 2016551037A JP 2016551037 A JP2016551037 A JP 2016551037A JP 2016535769 A5 JP2016535769 A5 JP 2016535769A5
Authority
JP
Japan
Prior art keywords
alkyl
formula
represents hydrogen
here
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2016551037A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016535769A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2014/073800 external-priority patent/WO2015067651A1/de
Publication of JP2016535769A publication Critical patent/JP2016535769A/ja
Publication of JP2016535769A5 publication Critical patent/JP2016535769A5/ja
Ceased legal-status Critical Current

Links

JP2016551037A 2013-11-08 2014-11-05 キマーゼ阻害薬としての置換されているウラシル類 Ceased JP2016535769A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13192183 2013-11-08
EP13192183.5 2013-11-08
PCT/EP2014/073800 WO2015067651A1 (de) 2013-11-08 2014-11-05 Substituierte uracile als chymase inhibitoren

Publications (2)

Publication Number Publication Date
JP2016535769A JP2016535769A (ja) 2016-11-17
JP2016535769A5 true JP2016535769A5 (enExample) 2017-12-14

Family

ID=49582563

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016551037A Ceased JP2016535769A (ja) 2013-11-08 2014-11-05 キマーゼ阻害薬としての置換されているウラシル類

Country Status (7)

Country Link
US (2) US9695131B2 (enExample)
EP (1) EP3066096A1 (enExample)
JP (1) JP2016535769A (enExample)
CN (1) CN105873919A (enExample)
CA (1) CA2929763A1 (enExample)
HK (1) HK1224288A1 (enExample)
WO (1) WO2015067651A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014345599B2 (en) * 2013-11-08 2019-02-14 Bayer Pharma Aktiengesellschaft Salts of 1-(3-Methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-2,4-dioxo-3-[(1R)- 4-(trifluormethyl)-2,3-dihydro-1H-inden-1-yl]-1,2,3,4-tetrahydropyrimidin-5-carboxylic acid
EP3338780A1 (de) 2016-12-20 2018-06-27 Bayer Pharma Aktiengesellschaft Verwendung von chymaseinhibitoren zur behandlung von endometriose, post-operativer fibrose und erkrankungen die durch fibrosebildung gekennzeichnet sind
EP3615031A1 (en) * 2017-04-27 2020-03-04 Bayer Aktiengesellschaft Selective adrenoreceptor alpha2c receptor antagonists alone, or in combination with chymase inhibitors for use in the treatment and/or prophylaxis of peripheral artery diseases (pad)
CN113811530B (zh) * 2019-07-03 2022-07-19 南京明德新药研发有限公司 作为糜酶抑制剂的嘧啶酮类化合物及其应用
GB201918414D0 (en) 2019-12-13 2020-01-29 Z Factor Ltd Compounds and their use for the treatment of Alpha1-Antitrypsin deficiency
WO2021252951A1 (en) 2020-06-12 2021-12-16 Vanderbilt University Methods of treatment for gastrointestinal motility disorders
WO2022135534A1 (zh) * 2020-12-25 2022-06-30 广东东阳光药业有限公司 取代的含氮双环化合物及其用途
CN114671856B (zh) * 2020-12-25 2023-10-20 广东东阳光药业股份有限公司 多取代的尿嘧啶衍生物及其用途
CN114685472B (zh) * 2020-12-25 2024-04-26 广东东阳光药业股份有限公司 多取代的尿嘧啶衍生物及其用途
AU2023251136A1 (en) 2022-04-05 2024-10-17 Bayer Aktiengesellschaft Inhibitors of chymase for use in the selective resolution of thrombi in thrombotic or thromboembolic disorders
CN118994100A (zh) * 2023-05-22 2024-11-22 苏州大学 一种二酮类化合物及其制备方法与应用
CN119019341B (zh) * 2023-05-23 2025-11-18 苏州大学 一种腈类化合物及其制备方法与应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3086095A (en) * 1994-07-29 1996-03-04 Suntory Limited Imidazolidine derivative and use thereof
CA2219364A1 (en) * 1995-04-27 1996-10-31 Hideki Okunishi Heterocyclic amide compounds and pharmaceutical use thereof
AU723234B2 (en) * 1996-09-06 2000-08-24 Nippon Kayaku Kabushiki Kaisha Novel acetamide derivatives and protease inhibitors
JPH10195063A (ja) 1996-10-21 1998-07-28 Dai Ichi Seiyaku Co Ltd エチニルチアゾール誘導体
CN1088706C (zh) * 1996-10-25 2002-08-07 卫福有限公司 新型杂环酰胺化合物及其医药用途
CN1209368C (zh) * 1998-02-17 2005-07-06 日本化药株式会社 新的乙酰胺衍生物及其用途
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
EP1192950B1 (en) * 2000-02-22 2006-07-26 Daiichi Asubio Pharma Co., Ltd. Therapeutic drugs for dermatitis exhibiting a biphasic skin reaction containing chymase inhibitors as the active ingredient
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
JP2009520038A (ja) 2005-12-19 2009-05-21 ジェネンテック・インコーポレーテッド ピリミジンキナーゼインヒビター
WO2007122634A2 (en) * 2006-04-24 2007-11-01 Jubilant Biosys Limited Pyrimidinediones as tyrosine kinase inhibitors
AR061570A1 (es) 2006-06-23 2008-09-03 Smithkline Beecham Corp Compuesto de glicina sustituido en el n heteroaromatico composicion farmaceutica que lo comprende, su uso para preparar un medicamento, procedimientos para preparar dicha composicion farmaceutica y para preparar el compuesto
US7790756B2 (en) 2006-10-11 2010-09-07 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
GB0622472D0 (en) 2006-11-10 2006-12-20 Addex Pharmaceuticals Sa Novel heterocyclic derivatives
CA2676173A1 (en) 2007-02-16 2008-08-28 Amgen Inc. Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors
WO2009049112A1 (en) 2007-10-10 2009-04-16 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
DE102008030091B4 (de) 2008-06-25 2011-03-03 Resprotect Gmbh Uracilderivate und deren Verwendung
ES2610158T3 (es) 2008-08-15 2017-04-26 Nivalis Therapeutics, Inc. Nuevos inhibidores pirrólicos de S-nitrosoglutatión reductasa como agentes terapéuticos
AU2012339640B2 (en) 2011-11-14 2017-01-05 Ignyta, Inc. Uracil derivatives as AXL and c-MET kinase inhibitors
UA112897C2 (uk) * 2012-05-09 2016-11-10 Байєр Фарма Акцієнгезелльшафт Біциклічно заміщені урацили та їх застосування для лікування і/або профілактики захворювань

Similar Documents

Publication Publication Date Title
JP2016535769A5 (enExample)
JP2015516000A5 (enExample)
RU2010129724A (ru) 4-(4-циано-2-тиоарил)-дигидропиримидиноны и их применение
JP2016536362A5 (enExample)
CA2749040A1 (en) Triazolo and tetrazolo pyrimidine derivatives as hne inhibitors for treating copd
JP2012522814A5 (enExample)
JP2019522628A5 (enExample)
JP2011513410A5 (enExample)
JP2016535095A5 (enExample)
CA2723559A1 (en) 1,4-diaryl-pyrimidopyridazine-2,5-diones and their use
JP2016525075A5 (enExample)
JP2019094345A5 (enExample)
JP2007524696A5 (enExample)
JP2010507602A5 (enExample)
JP2009515988A5 (enExample)
HRP20171189T1 (hr) Bisaril-vezani ariltriazoloni i njihova uporaba
HRP20220899T1 (hr) Spojevi policikličkog karbamoilpiridona i njihova farmaceutska uporaba
JP2011515398A5 (enExample)
JP2012528166A5 (enExample)
RU2010121763A (ru) Производные пиридазинона и ингибиторы р2х7 рецептора
JP2016525136A5 (enExample)
JP2010513272A5 (enExample)
JP2010513322A5 (enExample)
JP2010501478A5 (enExample)
JP2016540742A5 (enExample)